Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price ...
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...
Akebia TherapeuticsQ3每股收益及营收逊于预期
英为财情Investing.com - Akebia Therapeutics (NASDAQ: AKBA)星期四发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.100，总营收为$37.43M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$44.5M，每股收益为$-0.06 ...
Akebia Q3 2024 Earnings Preview
Akebia (NASDAQ:AKBA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open. The ...
Akebia Therapeutics Prepares for Vafseo Launch
Akebia Therapeutics ( (AKBA) ) has released its Q3 earnings. Here is a breakdown of the information Akebia Therapeutics presented to its ...
bovnews2 天
AKBA’s Latest Twist: What’s Fueling the Unexpected Shifts in Akebia Therapeutics Inc ...
BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...
bovnews5 天
Why Did Akebia Therapeutics Inc (AKBA) Stock Surge 14.79% Last Week?
BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised ...
Morningstar8 天
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...
Zacks.com on MSN7 天
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures ...
Seeking Alpha7 天
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's ...
Akebia公布第三季度业绩，为Vafseo上市做准备
Akebia Therapeutics, Inc. (NASDAQ: AKBA) 于2024年11月7日讨论了其第三季度财务业绩，重点关注其贫血药物Vafseo（vadadustat）将于2025年1月在美国市场上市的准备工作。尽管总收入从去年同期的4200万美元降至3740万美元，但公司对Vafseo在透析和非透析慢性肾病患者群体中的潜力持乐观态度。 Akebia已经获得了报销协议，并正在积极与 ...